Is Pfizer Stock Underperforming the S&P 500?

Based in New York, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and delivers medicines and vaccines. Its portfolio spans wellness, prevention, treatments, and cures across multiple therapeutic areas, supported by a broad pipeline of innovative healthcare products. It has a market capitalization of $159.4 billion.

Companies worth $10 billion to $200 billion are generally described as “large-cap stocks,” and PFE definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance within the General Drug Manufacturers industry.

PFE stands out for its powerful global brand, diverse portfolio of leading medicines and vaccines, and strong research and development capabilities. Its significant international presence, including emerging markets, broadens revenue sources, while its robust pipeline supports future innovation and long-term growth.

PFE is currently 2.7% below its 52-week high of $28.75, reached on April 2, 2026. The stock has also gained 7% over the past three months, outpacing the S&P 500 ($SPX), which has risen 2% during that period.

Shares of PFE have gained 12.3% year-to-date and 13.7% over the past 52 weeks, slightly trailing the S&P 500’s 12.7% YTD gain and 18.6% return over the past year.

PFE has been trading above its 50-day and 200-day moving averages since early August, underscoring a bullish trend.

On August 4, PFE shares rose about 1.5% after the company reported its Q2 results. Adjusted EPS of 77 cents surpassed Wall Street’s expectation of 68 cents, while revenue of $15.03 billion also beat analysts’ forecast of $14.45 billion. PFE has lagged the broader market over the past year as investors remain cautious about declining COVID-related revenue, reliance on aging blockbuster drugs, and multiple upcoming patent expirations that could weigh on near-term growth.

Within the competitive General Drug Manufacturers industry, Eli Lilly and Company (LLY) has outperformed PFE, gaining 9.3% in 2026 and 60.5% over the past year.

Wall Street analysts are somewhat bullish on PFE’s prospects. The stock carries a consensus “Moderate Buy” rating from the 28 analysts covering it, while the mean price target of $28.60 implies 2.3% upside from current levels.